Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,043 | -8,522 | -6,009 | -4,185 | -2,161 |
| Depreciation Amortization | 182 | 628 | 449 | 290 | 142 |
| Accounts payable and accrued liabilities | 3 | 519 | -70 | 16 | 129 |
| Other Working Capital | -147 | 647 | 256 | 376 | 285 |
| Other Operating Activity | 91 | 254 | 869 | 484 | 256 |
| Operating Cash Flow | $-2,915 | $-6,475 | $-4,506 | $-3,020 | $-1,348 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2 | -91 | -37 | -10 | -11 |
| Investing Cash Flow | $-2 | $-91 | $-37 | $-10 | $-11 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -61 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | 13,068 | 13,158 | 5,735 | 4,042 |
| Other Financing Activity | 2 | 12 | 5 | 12 | 0 |
| Financing Cash Flow | $-59 | $13,079 | $13,163 | $5,747 | $4,042 |
| Beginning Cash Position | 8,988 | 2,474 | 2,474 | 2,474 | 2,474 |
| End Cash Position | 6,011 | 8,988 | 11,094 | 5,191 | 5,157 |
| Net Cash Flow | $-2,976 | $6,514 | $8,620 | $2,717 | $2,683 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,915 | -6,475 | -4,506 | -3,020 | -1,348 |
| Capital Expenditure | -2 | -91 | -37 | -10 | -11 |
| Free Cash Flow | -2,917 | -6,566 | -4,543 | -3,030 | -1,359 |